{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-22-017922","form_type":"8-K","ticker":"AYTU","cik":"0001385818","company_name":"AYTU BIOPHARMA, INC","filed_at":"2022-11-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.400031+00:00","generated_at":"2026-06-21T18:19:14.862212+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Aytu BioPharma appoints Christopher Brooke as COO, effective Nov 14, 2022","bullets":["Christopher Brooke previously served as EVP Rare Disease Development since April 2021.","Brooke holds a 47.5% ownership interest in Rumpus, from which Aytu acquired enzastaurin license.","Aytu paid $4.0M in milestones to Rumpus in fiscal 2022 ($2.6M cash + 2,188,940 shares).","Brooke has over 20 years healthcare management experience at Johnson & Johnson, AstraZeneca, and AmerisourceBergen."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-22-017922","json":"https://secwatch.observer/filing/0001558370-22-017922.json","markdown":"https://secwatch.observer/filing/0001558370-22-017922.md","text":"https://secwatch.observer/filing/0001558370-22-017922.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1385818/000155837022017922/0001558370-22-017922-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1385818/000155837022017922/aytu-20221115x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T18:19:14.862212+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4cee272682","claim":"Christopher Brooke was appointed as Chief Operating Officer at AYTU BIOPHARMA, INC.","evidence_excerpt":"Effective November 14, 2022, Aytu BioPharma, Inc. (the “Company”) appointed Christopher Brooke as Chief Operating Officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1385818/000155837022017922/0001558370-22-017922-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Operating Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}